I have another blog that deals with U.S. employment data from the information sector. This one provides May 2010 employment and wage data from fourteen 4- and 5-digit NAICS industry groups in the “Information Sector.”
Notes on the data
The Office of the U.S. Trade Representative (USTR) has declared an intention to have all its proposals on intellectual property protections by the commencement of the next round of TPP talks in Vietnam June 20-24, 2011. On a fast timetable, TPP negotiators have already announced that they want to finalize TPP by the summit meetings of the members of the Asia-Pacific Economic Cooperation on November 8-13, 2011 in Hawaii. The TPP will impact health, access to knowledge, and without the necessary safeguards, the right to privacy.
In a major breakthrough on the WIPO negotiations on copyright exceptions for persons with disabilities, at around 1pm today, a non-paper “resulting from informal discussions among Argentina, Brazil, Ecuador, the European Union and its Member States, Mexico, Paraguay and the United States of America” was distributed at the WIPO SCCR 22.
A copy of the document is available here:
/wp-content/uploads/text_distributed_friday_1pm.doc
 |
| Members of the WBU delegation at WIPO SCCR 22 |
June 16, 10 am: There are good news and less good news to report from Geneva. While overall, things have moved in positive directions, with the US and the EU engaged in very constructive negotiations with Brazil and other treaty sponsors, there are still many frustrations. Continue Reading
Using industry assertions of R&D spending, pharmaceutical related R&D spending by the private sector was less than 8 percent of global sales in 2010.
These are the data:
2010 Global R&D by all private companies: – $67.4 billion
Source: Page 2 of the 2011 PhRMA industry profile
http://report.nih.gov/investigators_and_trainees/acd_bwf/pdf/Phrma_Industry_Profile_2011.pdf
2010 Global sales – $856 billion
Continue Reading
This is a report from the FDA on 2011 new molecular entities (NMEs) approvals, through June 6, 2011. The total number of FDA approvals during that same period was 150. So far, 16 NMEs have been approved in five months, a sharp increase in approvals over the same period 2010.
6 NMEs NDAs were considered priorities
8 NDAs that were considered standard approvals
2 BLA (biologic products) that were not classified.
On Thursday, May 26, 2011, Senator Bernie Sanders (I-VT) introduced two bills in the United States Senate that would de-link R&D costs from drug prices. The bill names and numbers are as follows:
24 May 2011
NGO letter on Conflicts of Interest, Future Financing, Reform and governance of the WHO.
Dear Members of the Executive Board,